Apolipoprotein M: A novel adipokine decreasing with obesity and upregulated by calorie restriction
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Apolipoprotein M : A novel adipokine decreasing with obesity and upregulated by calorie restriction. / Sramkova, Veronika; Berend, Sarah; Siklova, Michaela; Caspar-Bauguil, Sylvie; Carayol, Jcrossed; Bonnel, Sophie; Marques, Marie; Decaunes, Pauline; Kolditz, Catherine Ines; Dahlman, Ingrid; Arner, Peter; Stich, Vladimir; Saris, Wim H M; Astrup, Arne; Valsesia, Armand; Rossmeislova, Lenka; Langin, Dominique; Viguerie, Nathalie.
In: American Journal of Clinical Nutrition, Vol. 109, No. 6, 2019, p. 1499-1510.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Apolipoprotein M
T2 - A novel adipokine decreasing with obesity and upregulated by calorie restriction
AU - Sramkova, Veronika
AU - Berend, Sarah
AU - Siklova, Michaela
AU - Caspar-Bauguil, Sylvie
AU - Carayol, Jcrossed
AU - Bonnel, Sophie
AU - Marques, Marie
AU - Decaunes, Pauline
AU - Kolditz, Catherine Ines
AU - Dahlman, Ingrid
AU - Arner, Peter
AU - Stich, Vladimir
AU - Saris, Wim H M
AU - Astrup, Arne
AU - Valsesia, Armand
AU - Rossmeislova, Lenka
AU - Langin, Dominique
AU - Viguerie, Nathalie
N1 - CURIS 2019 NEXS 256
PY - 2019
Y1 - 2019
N2 - Background: The adipose tissue (AT) is a secretory organ producing a wide variety of factors that participate in the genesis of metabolic disorders linked to excess fat mass. Weight loss improves obesityrelated disorders. Objectives: Transcriptomic studies on human AT, and a combination of analyses of transcriptome and proteome profiling of conditioned media from adipocytes and stromal cells isolated from human AT, have led to the identification of apolipoprotein M (apoM) as a putative adipokine. We aimed to validate apoM as novel adipokine, investigate the relation of AT APOM expression with metabolic syndrome and insulin sensitivity, and study the regulation of its expression in AT and secretion during calorie restriction-induced weight loss. Methods: We examined APOM mRNA level and secretion in AT from 485 individuals enrolled in 5 independent clinical trials, and in vitro in human multipotent adipose-derived stem cell adipocytes. APOM expression and secretion were measured during dieting. Results: APOM was expressed in human subcutaneous and visceral AT, mainly by adipocytes. ApoM was released into circulation from AT, and plasma apoM concentrations correlate with AT APOM mRNA levels. In AT, APOM expression inversely correlated with adipocyte size, was lower in obese compared to lean individuals, and reduced in subjects with metabolic syndrome and type 2 diabetes. Regardless of fat depot, there was a positive relation between AT APOM expression and systemic insulin sensitivity, independently of fatmass and plasma HDL cholesterol. In human multipotent adiposederived stem cell adipocytes, APOM expression was enhanced by insulin-sensitizing peroxisome proliferator-activated receptor agonists and inhibited by tumor necrosis factor ?, a cytokine that causes insulin resistance. In obese individuals, calorie restriction increased AT APOM expression and secretion. Conclusions: ApoM is a novel adipokine, the expression of which is a hallmark of healthy AT and is upregulated by calorie restriction. AT apoM deserves further investigation as a potential biomarker of risk for diabetes and cardiovascular diseases.
AB - Background: The adipose tissue (AT) is a secretory organ producing a wide variety of factors that participate in the genesis of metabolic disorders linked to excess fat mass. Weight loss improves obesityrelated disorders. Objectives: Transcriptomic studies on human AT, and a combination of analyses of transcriptome and proteome profiling of conditioned media from adipocytes and stromal cells isolated from human AT, have led to the identification of apolipoprotein M (apoM) as a putative adipokine. We aimed to validate apoM as novel adipokine, investigate the relation of AT APOM expression with metabolic syndrome and insulin sensitivity, and study the regulation of its expression in AT and secretion during calorie restriction-induced weight loss. Methods: We examined APOM mRNA level and secretion in AT from 485 individuals enrolled in 5 independent clinical trials, and in vitro in human multipotent adipose-derived stem cell adipocytes. APOM expression and secretion were measured during dieting. Results: APOM was expressed in human subcutaneous and visceral AT, mainly by adipocytes. ApoM was released into circulation from AT, and plasma apoM concentrations correlate with AT APOM mRNA levels. In AT, APOM expression inversely correlated with adipocyte size, was lower in obese compared to lean individuals, and reduced in subjects with metabolic syndrome and type 2 diabetes. Regardless of fat depot, there was a positive relation between AT APOM expression and systemic insulin sensitivity, independently of fatmass and plasma HDL cholesterol. In human multipotent adiposederived stem cell adipocytes, APOM expression was enhanced by insulin-sensitizing peroxisome proliferator-activated receptor agonists and inhibited by tumor necrosis factor ?, a cytokine that causes insulin resistance. In obese individuals, calorie restriction increased AT APOM expression and secretion. Conclusions: ApoM is a novel adipokine, the expression of which is a hallmark of healthy AT and is upregulated by calorie restriction. AT apoM deserves further investigation as a potential biomarker of risk for diabetes and cardiovascular diseases.
KW - Adipokine
KW - Adipose tissue
KW - Calorie restriction
KW - Diet
KW - Glucose homeostasis
KW - Insulin resistance
KW - Lipocalin
KW - Metabolic syndrome
KW - Obesity
U2 - 10.1093/ajcn/nqy331
DO - 10.1093/ajcn/nqy331
M3 - Journal article
C2 - 30869115
AN - SCOPUS:85067291027
VL - 109
SP - 1499
EP - 1510
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - 6
ER -
ID: 225432018